Tamoxifen

Property	Information
Drug Name	Tamoxifen
FDA Approval	Yes (for breast cancer treatment)
Used for	Investigational use in glioblastoma (GBM) treatment
Clinical Trial Phase	Phase II clinical trials and retrospective studies
Clinical Trial Explanation	Not specified
Common Side Effects	Increased risk of blood clots, uterine cancer in women, impotence, and loss of libido in men, weight gain
OS without	Not specified
OS with	Varies; in gliomas, doses range from 160-240 mg per day showed tumor regression in 25% of patients
PFS without	Median survival time for GBM typically ranges from 3-7 months with second-line chemotherapy
PFS with	Median survival of 16 months for Grade III tumors and 7.2 months for GBM with tamoxifen treatment
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	Not specified
Toxicity Explanation	Not specified

Notes: Tamoxifen, a well-known breast cancer therapy, inhibits protein kinase C in gliomas, potentially slowing cancer cell growth and stimulating angiogenesis at high doses. Early studies indicate its promise in tumor regression and survival extension, with some patients experiencing major benefits. Its effectiveness and side effects, especially at high doses required for glioma treatment, highlight the need for further research to identify responsive patient groups and optimize treatment protocols.

From Ben Williams Book: Not specified

Loading comments...